Rothschild Investment Corp IL boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 44,840 shares of the medical research company’s stock after purchasing an additional 75 shares during the quarter. Thermo Fisher Scientific makes up about 1.5% of Rothschild Investment Corp IL’s portfolio, making the stock its 11th largest position. Rothschild Investment Corp IL’s holdings in Thermo Fisher Scientific were worth $13,061,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the stock. Camden National Bank lifted its position in shares of Thermo Fisher Scientific by 8.4% in the 3rd quarter. Camden National Bank now owns 774 shares of the medical research company’s stock worth $225,000 after acquiring an additional 60 shares during the period. Clarus Wealth Advisors lifted its position in shares of Thermo Fisher Scientific by 256.8% in the 3rd quarter. Clarus Wealth Advisors now owns 2,833 shares of the medical research company’s stock worth $825,000 after acquiring an additional 2,039 shares during the period. Welch & Forbes LLC lifted its position in shares of Thermo Fisher Scientific by 3.0% in the 3rd quarter. Welch & Forbes LLC now owns 59,399 shares of the medical research company’s stock worth $17,301,000 after acquiring an additional 1,755 shares during the period. Abner Herrman & Brock LLC lifted its position in shares of Thermo Fisher Scientific by 1.1% in the 3rd quarter. Abner Herrman & Brock LLC now owns 40,175 shares of the medical research company’s stock worth $11,702,000 after acquiring an additional 455 shares during the period. Finally, Buffington Mohr McNeal lifted its position in shares of Thermo Fisher Scientific by 1.0% in the 3rd quarter. Buffington Mohr McNeal now owns 31,349 shares of the medical research company’s stock worth $9,131,000 after acquiring an additional 325 shares during the period. Hedge funds and other institutional investors own 88.18% of the company’s stock.
In related news, CEO Marc N. Casper sold 2,271 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the sale, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at approximately $84,483,596. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the sale, the director now directly owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,104 shares of company stock valued at $15,418,539. 0.45% of the stock is currently owned by insiders.
A number of analysts have commented on TMO shares. Needham & Company LLC raised their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. Credit Suisse Group reissued a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Finally, ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $305.27.
Shares of TMO traded up $2.99 during mid-day trading on Friday, reaching $283.65. The company had a trading volume of 81,164 shares, compared to its average volume of 1,624,854. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.07. The company’s 50-day moving average is $287.07 and its 200-day moving average is $280.74. The company has a market capitalization of $108.90 billion, a P/E ratio of 25.51, a P/E/G ratio of 1.78 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The business had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. During the same period in the prior year, the firm posted $2.75 EPS. Thermo Fisher Scientific’s quarterly revenue was up 3.9% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 12.25 EPS for the current fiscal year.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What can cause a stock to outperform?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.